Status:
COMPLETED
Haemostatic Markers in Cardiopulmonary Bypass
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Royal Brompton & Harefield NHS Foundation Trust
Conditions:
Unfractionated Heparin
Cardiopulmonary Bypass Surgery
Eligibility:
All Genders
18+ years
Brief Summary
This study is to understand the changes occurring in a blood clotting protein, von Willebrand factor (VWF), in patients undergoing cardiac surgery who receive the blood thinner called Heparin. These p...
Detailed Description
Von Willebrand factor (VWF) is a large plasma glycoprotein involved in thrombosis, haemostasis and vascular biology. Its principal role is to capture platelets at sites of blood vessel endothelial inj...
Eligibility Criteria
Inclusion
- Patients undergoing first time cardiopulmonary bypass surgery for correction of atrial septal defects or tissue mitral valve repair
- Receiving intravenous Heparin for cardiopulmonary bypass
Exclusion
- Concomitant Aortic Stenosis which is associated with an acquired von Willebrand Syndrome (aVWS)
- Patients with a baseline platelet count of \<100x109/L
- Patients with a known coagulation factor deficiency or platelet function disorder
- Patients receiving heparin therapy prior to CPB within last 7 days
Key Trial Info
Start Date :
February 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03861286
Start Date
February 15 2019
End Date
July 18 2019
Last Update
September 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital
London, United Kingdom, SW3 6NP